Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Houston, TX
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Costa Mesa, CA
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Orlando, FL
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
Knoxville, TN
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  11/1/2013
Clinical Research Facility
mi
from
San Antonio, TX
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 11/1/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
An Open-Label Study to Evaluate the Pharmacokinetics of Multiple Oral Doses of 30 mg JNJ-38518168 in Subjects With Mild and Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Orlando, FL
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
An Open-Label Study to Evaluate the Pharmacokinetics of Multiple Oral Doses of 30 mg JNJ-38518168 in Subjects With Mild and Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
An Open-Label Study to Evaluate the Pharmacokinetics of Multiple Oral Doses of 30 mg JNJ-38518168 in Subjects With Mild and Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
Knoxville, TN
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
An Open-Label Study to Evaluate the Pharmacokinetics of Multiple Oral Doses of 30 mg JNJ-38518168 in Subjects With Mild and Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
An Open-Label Study to Evaluate the Pharmacokinetics of Multiple Oral Doses of 30 mg JNJ-38518168 in Subjects With Mild and Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Status: Enrolling
Updated:  11/8/2013
Clinical Research Facility
mi
from
San Antonio, TX
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
An Open-Label Study to Evaluate the Pharmacokinetics of Multiple Oral Doses of 30 mg JNJ-38518168 in Subjects With Mild and Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Status: Enrolling
Updated: 11/8/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Effect of Zinc on Barrett's Metaplasia
Effect of Zinc on Barrett's Metaplasia
Status: Enrolling
Updated:  11/8/2013
The Lankenau Institute for Medical Research
mi
from
Wynnewood, PA
Effect of Zinc on Barrett's Metaplasia
Effect of Zinc on Barrett's Metaplasia
Status: Enrolling
Updated: 11/8/2013
The Lankenau Institute for Medical Research
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents
Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents
Status: Enrolling
Updated:  11/11/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents
Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents
Status: Enrolling
Updated: 11/11/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Photometric Stereo Endoscopy (PSE) as a Tool for Imaging the Rectum and Colon
Pilot Study to Evaluate Photometric Stereo Endoscopy (PSE) as a Tool for Imaging the Rectum and Colon
Status: Enrolling
Updated:  11/15/2013
Massachusetts General Hospital
mi
from
Boston, MA
Photometric Stereo Endoscopy (PSE) as a Tool for Imaging the Rectum and Colon
Pilot Study to Evaluate Photometric Stereo Endoscopy (PSE) as a Tool for Imaging the Rectum and Colon
Status: Enrolling
Updated: 11/15/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Status: Enrolling
Updated:  11/19/2013
Texas Tech University Health Sciences Center at El Paso
mi
from
El Paso, TX
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Status: Enrolling
Updated: 11/19/2013
Texas Tech University Health Sciences Center at El Paso
mi
from
El Paso, TX
Click here to add this to my saved trials
A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate
A Double-Blinded Randomized Controlled CER Study of Changes in Bone Mineral Density, Blood Chemistries, Self-Reported Quality of Life and Compliance as a Function of Consuming Micronized Versus Non-micronized Calcium Carbonate
Status: Enrolling
Updated:  11/21/2013
Integrative Health Technologies
mi
from
San Antonio, TX
A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate
A Double-Blinded Randomized Controlled CER Study of Changes in Bone Mineral Density, Blood Chemistries, Self-Reported Quality of Life and Compliance as a Function of Consuming Micronized Versus Non-micronized Calcium Carbonate
Status: Enrolling
Updated: 11/21/2013
Integrative Health Technologies
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
City of Hope National Medical Center
mi
from
Duarte, CA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
City of Hope Medical Group
mi
from
South Pasadena, CA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
City of Hope Medical Group
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Mayo Clinic Florida
mi
from
Jacksonville, FL
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Moffitt Cancer Centre and Research Institute
mi
from
Tampa, FL
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Moffitt Cancer Centre and Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
UH Case Medical Center
mi
from
Cleveland, OH
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
UH Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
Status: Enrolling
Updated:  12/11/2013
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
Status: Enrolling
Updated: 12/11/2013
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment
Atomoxetine Treatment for Opioid Maintained Cocaine Users
Status: Enrolling
Updated:  12/12/2013
Department of Veterans Affairs Hospital
mi
from
West Haven, CT
A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment
Atomoxetine Treatment for Opioid Maintained Cocaine Users
Status: Enrolling
Updated: 12/12/2013
Department of Veterans Affairs Hospital
mi
from
West Haven, CT
Click here to add this to my saved trials
A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
Status: Enrolling
Updated:  12/17/2013
Advanced Clinical Research Institute
mi
from
Anaheim, CA
A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
Status: Enrolling
Updated: 12/17/2013
Advanced Clinical Research Institute
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
Status: Enrolling
Updated:  12/17/2013
DaVita Clinical Research
mi
from
Lakewood, CO
A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
Status: Enrolling
Updated: 12/17/2013
DaVita Clinical Research
mi
from
Lakewood, CO
Click here to add this to my saved trials
A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
Status: Enrolling
Updated:  12/17/2013
ClinPharm Miami
mi
from
Miami, FL
A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
Status: Enrolling
Updated: 12/17/2013
ClinPharm Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
Status: Enrolling
Updated:  12/17/2013
Orlando Clinical Research
mi
from
Orlando, FL
A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
Status: Enrolling
Updated: 12/17/2013
Orlando Clinical Research
mi
from
Orlando, FL
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Precision Research Institute
mi
from
Chula Vista, CA
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Precision Research Institute
mi
from
Chula Vista, CA
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Precision Research Institute, LLC
mi
from
San Diego, CA
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Precision Research Institute, LLC
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Avail Clinical Research
mi
from
DeLand, FL
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
The Center for GI Disorders
mi
from
Hollywood, FL
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
The Center for GI Disorders
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Mid-Atlantic Medical Research Centers
mi
from
Hollywood, MD
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Mid-Atlantic Medical Research Centers
mi
from
Hollywood, MD
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
PharmaTrials
mi
from
Hillsborough, NJ
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
PharmaTrials
mi
from
Hillsborough, NJ
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Montefiore Medical Center
mi
from
Bronx, NY
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Gastroenterology Associates of Orangeburg, PA
mi
from
Orangeburg, SC
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Gastroenterology Associates of Orangeburg, PA
mi
from
Orangeburg, SC
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Birmingham, AL
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Little Rock, AR
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Roseville, CA
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Roseville, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
San Diego, CA
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/14/2014
Clinical Research Facility
mi
from
Golden, CO
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/14/2014
Clinical Research Facility
mi
from
Golden, CO
Click here to add this to my saved trials